Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Scandinavian ChemoTech AB (publ) specializes in providing therapeutic options for cancer and pain management. The company's flagship product is IQWave, an advanced electroporation system. This innovative device employs brief electrical pulses in conjunction with chemotherapy, which can be administered either regionally or systemically, to treat a variety of cancers. These include specific conditions such as head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma affecting the breast and salivary gland, hypernephroma, Kaposi sarcoma, and transitional cell carcinoma. The firm markets its technologies through a network of distribution partners and influential medical professionals, primarily focusing on markets in Southeast Asia, India, and the Philippines. Founded in 2013, Scandinavian ChemoTech AB (publ) is headquartered in Lund, Sweden.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of CMOTEC-B.ST is 6.3 and suggests 75% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to